Pneumonia Therapeutics Market: By Therapeutics (Prevention Vaccines and Treatment Drugs), Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), Age Group (Pediatric, Adult, and Geriatric), And Region (North America, Europe, Asia Pacific, Latin America, And MEA) And Forecast To 2029  

Pneumonia Therapeutics Market size was valued at USD 14,956.4 million in 2022 and is expected to grow at a CAGR of 8.7% from 2023-2029. Pneumonia is an inflammatory medical disorder that disturbs the alveoli and air sacs in the lungs. Pathogens such as viruses, bacteria, and fungi are the leading cause of pneumococcal infection using inhalation of air-borne droplets from coughing or sneezing. Pneumonia can also happen through contact with surfaces and objects that are soiled with pneumonia-causing viruses and bacteria.  According to the kind of case, the medicines are to be given. For example, if pneumonia is produced by bacteria, an antibiotic is prescribed. Pneumonia therapeutics comprise the approaches such as drugs and vaccinations that can support managing of the infection. The infection can be severe but are predominantly lethal to children, infants, and individuals over 65. The rising prevalence of pneumococcal disease can lead to the growth of the pneumonia therapeutics market. Moreover, the growing pollution level in the environment, the introduction of preventive vaccination programs, and improved standards introduced by healthcare facilities over the market are some primary factors that can boost the global pneumonia therapeutics market share. Apart from these, the increased prevalence rate of lung illnesses worldwide can also accelerate the market in the future. However, some factors, such as the absence of patient awareness and restricted access to therapy, may restrain the growth of the market. The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.

Pneumonia Therapeutics Market Key Developments:

• In October 2022, BioLink received funds to develop a Covid-19 pneumonia treatment.
• In August 2022, Pfizer announced positive top-line results from the Phase 3 Study of the 20-valent pneumococcal conjugate vaccine in infants.